JCR’s GVHD 1.5 Years Ahead Of Schedule, Application Planned For 2014
This article was originally published in PharmAsia News
Executive Summary
JCR Pharmaceuticals announced Nov. 19 they reached the target number of cases for domestic Phase II/III trials for JR-031, a drug the company is developing for the treatment of graft-versus-host disease, a serious complication that occurs during hematopoietic stem cell and bone marrow transplantation.